Biosimilar version of etanercept gains FDA approval

A biosimilar of etanercept received clearance for marketing from the Food and Drug Administration on Aug. 30 for all of the inflammatory disease indications held by the reference originator etanercept product, Enbrel, according to an announcement from the agency. Approval for all of Enbrel’s...
Source: Skin and Allergy News - Category: Dermatology Source Type: news